Dermatology Conference Coverage

Almost 20,000 dermatologists attended the annual meeting this weekend at the San Diego Convention Center.

The Incyte drug is headed for assessment in a phase 3 trial.

The 92-year-old "Star Trek" star said the skin cancer was treated surgically and with immunotherapy. It was apparently the first time he had discussed his melanoma in public.

The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.

Scabies, arsenic exposure and psychogenic pruritus are among the possibilities discussed in a poster presented at the annual meeting of the American Academy of Dermatology.

No safety signals emerged during the 26-month open label study of Vyjuvek (beremagene geperpavec), a topical gel approved as a treatment for dystrophic epidermolysis bullosa.

A "hit-it-hard, hit-it-early" strategy might eventually cure plaque psoriasis, said Andrew Blauvelt, M.D., MBA. Blauvelt presented promising data from his small study of high-dose Skyrizi (risankizumab), but the doses were not a cure and the disease "trickles back" albeit slowly, he said.

A phase 2 study demonstrated positive results for remibrutinib, a BTK inhibitor, as a treatment for patients with the rare skin condition, hidradenitis suppurativa, finds a study presented at the American Academy of Dermatology Association.

In a discussion with Managed Healthcare Executive, Robert Sidbury, M.D., M.P.H, FAAD, professor of pediatrics at the Seattle Children's Hospital talks about what it takes to run a dermatology practice and how to implement value-based care initiatives.

At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.

They range from skin conditions associated with sexually transmitted infections to acne to hair loss and removal for the alignment of appearance to gender identity.

People of color are more likely to develop atopic dermatitis and have more severe disease. Vtama, currently approved to treat plaque psoriasis, is being studied to treat patients with atopic dermatitis.

Body dysmorphia that focuses on self-perceptions of the face has been dubbed "Zoom dysmorphia" because of its association with the video conferencing platforms.

University of Chicago researchers documented the relative lack of pharmacies in the city's low-income neighborhoods and the higher price of lotions, creams and liquid body soaps recommended by the National Eczema Foundation.

A content analysis of 75 TikTok videos showed that most have positive information about the oral acne medication, which was previously sold under the brand name Accutane. But larger majority (77%) of the videos have negative information about isotretinoin, and a large percentage of those videos give the positive effects only a passing mention, if any at all.

In a discussion with Managed Healthcare Executive, Jonathan I. Silverberg, M.D., Ph.D., M.P.H., an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, discussed the concept of "atopic march."

Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.

Contrary to previously held beliefs, reactions are possible regardless of skin tone or age.

The annual meeting will run through Tuesday.

John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.

Sancy Leachman, M.D., Ph.D., professor and chair of the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University, discusses genetic testing for melanoma.

In his keynote at the annual meeting of the American Academy of Dermatology Association Safi R. Bahcall, Ph.D., a physicist and entrepreneur, spoke about how seemingly crazy ideas can lead to breakthroughs.

Findings from a mouse model suggest that encapsulating anandamide, an endocannabinoid, could be a way to make it an effective treatment for cutaneous lupus erythematosus (CLE).

VISIBLE is focused on answering data gaps in people of color with psoriasis. Lead investigator Andrew F. Alexis, M.D., hopes the study will generate data to help address care gaps and inform future best practices in diversity research in dermatology.

The researchers say their findings argue for dermatologists embracing TikTok and promoting more high-quality content on it and other social media platforms.

Checkpoint inhibitors, such as Keytruda (pembrolizumab) and Opdivo (nivolumab), are playing a major role in cancer treatment. But they also produce side effects that affect the skin. Steven Chen, M.D., M.P.H., M.H.P. Ed., said dermatologists need to work with oncologists to manage the side effects so patients can stay on checkpoint inhibitors.

Longer-term use of Opzelura was well tolerated, with no serious treatment-related adverse events, according to a poster presented at the annual dermatology meeting.

John E. Harris, M.D., Ph.D., of the UMass Chan Medical School in Worcester, Massachusetts, and director of a vitiligo clinic and research center there, discusses some of the insurance issues regarding Opzelura (ruxolitinib) cream.